Surgery Partners, Inc.

SGRY

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Rock Springs Capital Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 310,000Value: $4.8M

# Signal Note: Rock Springs Capital Initiates SGRY Position Rock Springs Capital's $4.8M entry into Surgery Partners suggests conviction in the ASC operator's operational leverage and margin expansion potential, likely tied to procedure volume recovery post-inflation and improved reimbursement tailwinds. As a healthcare specialist, the fund's concentrated approach indicates they see near-term catalysts—potentially Q4 earnings beats or 2024 guidance raises—that the market has underpriced relative to peers in the surgical services space.

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX2 funds MIRM2 funds NAMSW2 funds OMDA2 funds NUVB2 funds ALNY2 funds ACAD2 funds PHVS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

Deerfield's entry into SGRY signals confidence in the surgical services consolidation thesis, particularly as the company navigates post-COVID procedure volume normalization and margin expansion. The $1.7M position size is modest but notable given Deerfield's healthcare expertise; SGRY trades at depressed multiples (sub-10x EBITDA) despite improving operational leverage, suggesting potential near-term catalysts around quarterly earnings or refinancing activities.